Below are the financial statements of Swedish Orphan Biovitrum, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.
| All figures in millions of SEK | 2024 | 2023 |
|---|---|---|
| Total revenue | 26,027a | 22,123a |
| Cost of goods sold | -5,785a | -4,995a |
| Gross profit | 20,242a | 17,128a |
| Sales and administrative expenses | -11,085a | -10,161a |
| Research and development expenses | -3,538a | -2,796a |
| Other operating income | 14a | 9a |
| Other operating expenses | -7a | -115a |
| Operating profit | 5,625a | 4,066a |
| Financial income | 86a | 50a |
| Financial expenses | -1,305a | -1,162a |
| Net financial items | -1,219a | -1,112a |
| Profit before tax | 4,407a | 2,954a |
| Income tax | -528a | -546a |
| Profit for the year | 3,879a | 2,409a |
| Profit for the year attributable to | — | — |
| Owners of the parent company | 3,885a | 2,409a |
| Non-controlling interests | -6a | 0a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.